nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—HTR2B—cardial valve—dilated cardiomyopathy	0.126	0.623	CbGeAlD
Raloxifene—CYP2C8—Spironolactone—dilated cardiomyopathy	0.0489	1	CbGbCtD
Raloxifene—Gastrointestinal symptom NOS—Spironolactone—dilated cardiomyopathy	0.0386	0.0652	CcSEcCtD
Raloxifene—Tendon disorder—Lisinopril—dilated cardiomyopathy	0.0355	0.06	CcSEcCtD
Raloxifene—Breast pain—Spironolactone—dilated cardiomyopathy	0.026	0.044	CcSEcCtD
Raloxifene—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.0208	0.0352	CcSEcCtD
Raloxifene—Laryngitis—Lisinopril—dilated cardiomyopathy	0.0128	0.0217	CcSEcCtD
Raloxifene—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.0113	0.0192	CcSEcCtD
Raloxifene—Bladder pain—Furosemide—dilated cardiomyopathy	0.0112	0.0189	CcSEcCtD
Raloxifene—Breast pain—Lisinopril—dilated cardiomyopathy	0.0106	0.0179	CcSEcCtD
Raloxifene—SIGMAR1—cardiac ventricle—dilated cardiomyopathy	0.0106	0.0525	CbGeAlD
Raloxifene—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.0103	0.0174	CcSEcCtD
Raloxifene—Cough increased—Lisinopril—dilated cardiomyopathy	0.0101	0.0171	CcSEcCtD
Raloxifene—SIGMAR1—myocardium—dilated cardiomyopathy	0.00997	0.0494	CbGeAlD
Raloxifene—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00953	0.0161	CcSEcCtD
Raloxifene—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00926	0.0157	CcSEcCtD
Raloxifene—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00904	0.0153	CcSEcCtD
Raloxifene—ESR2—heart—dilated cardiomyopathy	0.00898	0.0445	CbGeAlD
Raloxifene—Cystitis—Lisinopril—dilated cardiomyopathy	0.00894	0.0151	CcSEcCtD
Raloxifene—AOX1—heart—dilated cardiomyopathy	0.00865	0.0428	CbGeAlD
Raloxifene—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00837	0.0142	CcSEcCtD
Raloxifene—ESR1—LKB1 signaling events—SIK1—dilated cardiomyopathy	0.008	0.0507	CbGpPWpGaD
Raloxifene—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00792	0.0134	CcSEcCtD
Raloxifene—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00773	0.0131	CcSEcCtD
Raloxifene—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00758	0.0128	CcSEcCtD
Raloxifene—AOX1—cardiac atrium—dilated cardiomyopathy	0.0074	0.0366	CbGeAlD
Raloxifene—ESR2—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00727	0.0461	CbGpPWpGaD
Raloxifene—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00699	0.0118	CcSEcCtD
Raloxifene—SIGMAR1—heart—dilated cardiomyopathy	0.00696	0.0345	CbGeAlD
Raloxifene—HTR2B—heart—dilated cardiomyopathy	0.00695	0.0344	CbGeAlD
Raloxifene—Arthritis—Lisinopril—dilated cardiomyopathy	0.00692	0.0117	CcSEcCtD
Raloxifene—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00686	0.0116	CcSEcCtD
Raloxifene—Sweating—Furosemide—dilated cardiomyopathy	0.00662	0.0112	CcSEcCtD
Raloxifene—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.0064	0.0108	CcSEcCtD
Raloxifene—ESR1—heart—dilated cardiomyopathy	0.00615	0.0305	CbGeAlD
Raloxifene—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00612	0.0103	CcSEcCtD
Raloxifene—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00608	0.0103	CcSEcCtD
Raloxifene—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00607	0.0103	CcSEcCtD
Raloxifene—SIGMAR1—cardiac atrium—dilated cardiomyopathy	0.00595	0.0295	CbGeAlD
Raloxifene—Influenza—Lisinopril—dilated cardiomyopathy	0.00581	0.00982	CcSEcCtD
Raloxifene—Angiopathy—Furosemide—dilated cardiomyopathy	0.00562	0.00951	CcSEcCtD
Raloxifene—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00559	0.00945	CcSEcCtD
Raloxifene—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00554	0.00936	CcSEcCtD
Raloxifene—Dizziness—Spironolactone—dilated cardiomyopathy	0.00535	0.00905	CcSEcCtD
Raloxifene—Flatulence—Furosemide—dilated cardiomyopathy	0.00532	0.00899	CcSEcCtD
Raloxifene—Weight increased—Lisinopril—dilated cardiomyopathy	0.00529	0.00894	CcSEcCtD
Raloxifene—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00521	0.00881	CcSEcCtD
Raloxifene—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00519	0.00877	CcSEcCtD
Raloxifene—Depression—Lisinopril—dilated cardiomyopathy	0.00517	0.00873	CcSEcCtD
Raloxifene—Vomiting—Spironolactone—dilated cardiomyopathy	0.00515	0.0087	CcSEcCtD
Raloxifene—Rash—Spironolactone—dilated cardiomyopathy	0.0051	0.00863	CcSEcCtD
Raloxifene—Dermatitis—Spironolactone—dilated cardiomyopathy	0.0051	0.00862	CcSEcCtD
Raloxifene—Headache—Spironolactone—dilated cardiomyopathy	0.00507	0.00857	CcSEcCtD
Raloxifene—ESR1—FOXM1 transcription factor network—LAMA4—dilated cardiomyopathy	0.00504	0.0319	CbGpPWpGaD
Raloxifene—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00504	0.00851	CcSEcCtD
Raloxifene—Sweating—Lisinopril—dilated cardiomyopathy	0.00497	0.0084	CcSEcCtD
Raloxifene—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00486	0.00822	CcSEcCtD
Raloxifene—Vertigo—Furosemide—dilated cardiomyopathy	0.00485	0.00819	CcSEcCtD
Raloxifene—Nausea—Spironolactone—dilated cardiomyopathy	0.00481	0.00813	CcSEcCtD
Raloxifene—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00466	0.00788	CcSEcCtD
Raloxifene—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00462	0.0078	CcSEcCtD
Raloxifene—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00459	0.00776	CcSEcCtD
Raloxifene—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00458	0.00774	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00456	0.00771	CcSEcCtD
Raloxifene—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00456	0.00771	CcSEcCtD
Raloxifene—CYP2B6—heart—dilated cardiomyopathy	0.00455	0.0225	CbGeAlD
Raloxifene—Shock—Furosemide—dilated cardiomyopathy	0.00433	0.00732	CcSEcCtD
Raloxifene—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00432	0.0073	CcSEcCtD
Raloxifene—Flushing—Lisinopril—dilated cardiomyopathy	0.00432	0.0073	CcSEcCtD
Raloxifene—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00431	0.00729	CcSEcCtD
Raloxifene—ESR2—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00429	0.0272	CbGpPWpGaD
Raloxifene—Skin disorder—Furosemide—dilated cardiomyopathy	0.00428	0.00723	CcSEcCtD
Raloxifene—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00426	0.0072	CcSEcCtD
Raloxifene—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00422	0.00713	CcSEcCtD
Raloxifene—Flatulence—Lisinopril—dilated cardiomyopathy	0.00399	0.00674	CcSEcCtD
Raloxifene—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00389	0.00658	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.0038	0.00643	CcSEcCtD
Raloxifene—Pain—Furosemide—dilated cardiomyopathy	0.00377	0.00637	CcSEcCtD
Raloxifene—ESR1—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00367	0.0232	CbGpPWpGaD
Raloxifene—Vertigo—Lisinopril—dilated cardiomyopathy	0.00364	0.00615	CcSEcCtD
Raloxifene—Syncope—Lisinopril—dilated cardiomyopathy	0.00363	0.00614	CcSEcCtD
Raloxifene—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.0036	0.00609	CcSEcCtD
Raloxifene—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00356	0.00601	CcSEcCtD
Raloxifene—Cough—Lisinopril—dilated cardiomyopathy	0.00353	0.00597	CcSEcCtD
Raloxifene—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00348	0.00588	CcSEcCtD
Raloxifene—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00348	0.00588	CcSEcCtD
Raloxifene—Myalgia—Lisinopril—dilated cardiomyopathy	0.00345	0.00583	CcSEcCtD
Raloxifene—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00345	0.00583	CcSEcCtD
Raloxifene—Chest pain—Lisinopril—dilated cardiomyopathy	0.00345	0.00583	CcSEcCtD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—ZBTB17—dilated cardiomyopathy	0.00344	0.0218	CbGpPWpGaD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00342	0.00579	CcSEcCtD
Raloxifene—HTR6—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00332	0.0211	CbGpPWpGaD
Raloxifene—Infection—Lisinopril—dilated cardiomyopathy	0.00328	0.00555	CcSEcCtD
Raloxifene—Shock—Lisinopril—dilated cardiomyopathy	0.00325	0.00549	CcSEcCtD
Raloxifene—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00323	0.00547	CcSEcCtD
Raloxifene—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00321	0.00542	CcSEcCtD
Raloxifene—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00319	0.0054	CcSEcCtD
Raloxifene—ESR2—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00306	0.0194	CbGpPWpGaD
Raloxifene—HTR2B—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00303	0.0192	CbGpPWpGaD
Raloxifene—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00301	0.00509	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00301	0.00509	CcSEcCtD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00299	0.019	CbGpPWpGaD
Raloxifene—Insomnia—Lisinopril—dilated cardiomyopathy	0.00299	0.00505	CcSEcCtD
Raloxifene—Dizziness—Furosemide—dilated cardiomyopathy	0.00291	0.00492	CcSEcCtD
Raloxifene—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00291	0.00492	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00285	0.00482	CcSEcCtD
Raloxifene—Pain—Lisinopril—dilated cardiomyopathy	0.00283	0.00478	CcSEcCtD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00282	0.0178	CbGpPWpGaD
Raloxifene—Vomiting—Furosemide—dilated cardiomyopathy	0.0028	0.00473	CcSEcCtD
Raloxifene—HTR6—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00279	0.0177	CbGpPWpGaD
Raloxifene—Rash—Furosemide—dilated cardiomyopathy	0.00278	0.00469	CcSEcCtD
Raloxifene—Dermatitis—Furosemide—dilated cardiomyopathy	0.00277	0.00469	CcSEcCtD
Raloxifene—ESR1—Nuclear signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.00276	0.0175	CbGpPWpGaD
Raloxifene—Headache—Furosemide—dilated cardiomyopathy	0.00276	0.00466	CcSEcCtD
Raloxifene—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.0027	0.00457	CcSEcCtD
Raloxifene—HTR6—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00269	0.0171	CbGpPWpGaD
Raloxifene—Nausea—Furosemide—dilated cardiomyopathy	0.00262	0.00442	CcSEcCtD
Raloxifene—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00261	0.00442	CcSEcCtD
Raloxifene—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00261	0.00442	CcSEcCtD
Raloxifene—ESR1—LKB1 signaling events—PSEN2—dilated cardiomyopathy	0.00256	0.0162	CbGpPWpGaD
Raloxifene—HTR2B—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00255	0.0162	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00253	0.016	CbGpPWpGaD
Raloxifene—HTR2B—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00246	0.0156	CbGpPWpGaD
Raloxifene—CYP19A1—FSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00231	0.0146	CbGpPWpGaD
Raloxifene—HTR6—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00226	0.0143	CbGpPWpGaD
Raloxifene—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00226	0.00382	CcSEcCtD
Raloxifene—Dizziness—Lisinopril—dilated cardiomyopathy	0.00218	0.00369	CcSEcCtD
Raloxifene—Vomiting—Lisinopril—dilated cardiomyopathy	0.0021	0.00355	CcSEcCtD
Raloxifene—Rash—Lisinopril—dilated cardiomyopathy	0.00208	0.00352	CcSEcCtD
Raloxifene—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00208	0.00352	CcSEcCtD
Raloxifene—Headache—Lisinopril—dilated cardiomyopathy	0.00207	0.0035	CcSEcCtD
Raloxifene—HTR2B—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00207	0.0131	CbGpPWpGaD
Raloxifene—Nausea—Lisinopril—dilated cardiomyopathy	0.00196	0.00332	CcSEcCtD
Raloxifene—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—RAF1—dilated cardiomyopathy	0.00189	0.012	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—NPPA—dilated cardiomyopathy	0.00179	0.0113	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.0017	0.0107	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00155	0.00981	CbGpPWpGaD
Raloxifene—CYP19A1—FSH signaling pathway—RAF1—dilated cardiomyopathy	0.00138	0.00876	CbGpPWpGaD
Raloxifene—EBP—Metabolism—ANKRD1—dilated cardiomyopathy	0.00133	0.00845	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.00129	0.00819	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00128	0.00808	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00126	0.00796	CbGpPWpGaD
Raloxifene—EBP—Metabolism—TAZ—dilated cardiomyopathy	0.00125	0.00795	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00119	0.00756	CbGpPWpGaD
Raloxifene—HTR6—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.00115	0.0073	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—GJA1—dilated cardiomyopathy	0.00114	0.00724	CbGpPWpGaD
Raloxifene—EBP—Metabolism—SDHA—dilated cardiomyopathy	0.00113	0.00719	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.00103	0.00656	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—IL10—dilated cardiomyopathy	0.00099	0.00628	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—RPS6KB1—dilated cardiomyopathy	0.000986	0.00625	CbGpPWpGaD
Raloxifene—HTR6—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.000933	0.00592	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.000931	0.0059	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000912	0.00578	CbGpPWpGaD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—dilated cardiomyopathy	0.000881	0.00559	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000858	0.00544	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—AGT—dilated cardiomyopathy	0.000832	0.00527	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—RAC1—dilated cardiomyopathy	0.000824	0.00522	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000818	0.00519	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000808	0.00512	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000807	0.00511	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000789	0.005	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000789	0.005	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000773	0.0049	CbGpPWpGaD
Raloxifene—CYP2C8—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000754	0.00478	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000739	0.00468	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000712	0.00451	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—TAZ—dilated cardiomyopathy	0.000695	0.0044	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000692	0.00438	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000674	0.00427	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000662	0.0042	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00065	0.00412	CbGpPWpGaD
Raloxifene—HTR2B—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000646	0.0041	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000641	0.00406	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.000633	0.00402	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—SDHA—dilated cardiomyopathy	0.000628	0.00398	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00061	0.00387	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00061	0.00387	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000606	0.00384	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—NR3C2—dilated cardiomyopathy	0.000605	0.00383	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000604	0.00383	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000585	0.00371	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000578	0.00367	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000567	0.00359	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000557	0.00353	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000557	0.00353	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000554	0.00351	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000549	0.00348	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000547	0.00347	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.000546	0.00346	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000527	0.00334	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.000526	0.00333	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000519	0.00329	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000518	0.00328	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000513	0.00325	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000501	0.00318	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.0005	0.00317	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000474	0.00301	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.000471	0.00298	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000469	0.00297	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000467	0.00296	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000464	0.00294	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000464	0.00294	CbGpPWpGaD
Raloxifene—HTR2B—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000455	0.00288	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000445	0.00282	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000439	0.00278	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000432	0.00274	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000428	0.00271	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000424	0.00269	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000424	0.00269	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000418	0.00265	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000413	0.00262	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000407	0.00258	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000406	0.00257	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—EGFR—dilated cardiomyopathy	0.000405	0.00257	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000398	0.00252	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000398	0.00252	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000394	0.0025	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000394	0.0025	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00039	0.00247	CbGpPWpGaD
Raloxifene—AOX1—Disease—NPPA—dilated cardiomyopathy	0.000384	0.00243	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000382	0.00242	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000382	0.00242	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—NPPA—dilated cardiomyopathy	0.00038	0.00241	CbGpPWpGaD
Raloxifene—AOX1—Disease—PSEN2—dilated cardiomyopathy	0.000372	0.00236	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—TAZ—dilated cardiomyopathy	0.000359	0.00228	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000357	0.00226	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000352	0.00223	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000339	0.00215	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000335	0.00212	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00033	0.00209	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000326	0.00207	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—SDHA—dilated cardiomyopathy	0.000325	0.00206	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.00031	0.00197	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000309	0.00196	CbGpPWpGaD
Raloxifene—EBP—Metabolism—GPX1—dilated cardiomyopathy	0.000308	0.00195	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NR3C2—dilated cardiomyopathy	0.000305	0.00193	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000301	0.00191	CbGpPWpGaD
Raloxifene—EBP—Metabolism—CD36—dilated cardiomyopathy	0.0003	0.0019	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000282	0.00179	CbGpPWpGaD
Raloxifene—EBP—Metabolism—AGT—dilated cardiomyopathy	0.00027	0.00171	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000262	0.00166	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000262	0.00166	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000259	0.00164	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000251	0.00159	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000245	0.00156	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000244	0.00155	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00024	0.00152	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00024	0.00152	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000239	0.00152	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000238	0.00151	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000238	0.00151	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000236	0.0015	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TAZ—dilated cardiomyopathy	0.000231	0.00146	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000229	0.00145	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000223	0.00141	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000222	0.0014	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000218	0.00138	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000218	0.00138	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000216	0.00137	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000215	0.00136	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000214	0.00136	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000213	0.00135	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SDHA—dilated cardiomyopathy	0.000209	0.00132	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	0.000208	0.00132	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000202	0.00128	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000202	0.00128	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000198	0.00126	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000196	0.00124	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	0.000195	0.00124	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000194	0.00123	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000193	0.00122	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NPPA—dilated cardiomyopathy	0.000192	0.00121	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000191	0.00121	CbGpPWpGaD
Raloxifene—AOX1—Disease—RAC1—dilated cardiomyopathy	0.000187	0.00119	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000184	0.00117	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000183	0.00116	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000177	0.00112	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	0.000177	0.00112	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000175	0.00111	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000174	0.0011	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000174	0.0011	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—GPX1—dilated cardiomyopathy	0.000171	0.00108	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000169	0.00107	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000167	0.00106	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CD36—dilated cardiomyopathy	0.000166	0.00105	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000159	0.00101	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000159	0.00101	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AGT—dilated cardiomyopathy	0.00015	0.000949	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000149	0.000942	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000145	0.000918	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000142	0.0009	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000141	0.000893	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000141	0.000893	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000136	0.00086	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000135	0.000856	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000131	0.00083	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00013	0.000822	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000129	0.000818	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000129	0.000815	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000129	0.000815	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000127	0.000804	CbGpPWpGaD
Raloxifene—AOX1—Disease—RAF1—dilated cardiomyopathy	0.000124	0.000786	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000123	0.000781	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000121	0.000764	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000119	0.000758	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000118	0.000746	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000116	0.000734	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000112	0.000707	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000108	0.000686	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000108	0.000683	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000107	0.000679	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000107	0.000679	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000105	0.000665	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000105	0.000665	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000103	0.000651	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.95e-05	0.000631	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.88e-05	0.000627	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.64e-05	0.000611	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	9.48e-05	0.000601	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.45e-05	0.000599	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.38e-05	0.000594	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.95e-05	0.000567	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.83e-05	0.00056	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GPX1—dilated cardiomyopathy	8.83e-05	0.00056	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CD36—dilated cardiomyopathy	8.6e-05	0.000545	CbGpPWpGaD
Raloxifene—AOX1—Disease—EGFR—dilated cardiomyopathy	8.51e-05	0.000539	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.23e-05	0.000522	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.17e-05	0.000518	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.06e-05	0.000511	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RAC1—dilated cardiomyopathy	7.97e-05	0.000506	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.81e-05	0.000495	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AGT—dilated cardiomyopathy	7.74e-05	0.000491	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AGT—dilated cardiomyopathy	7.62e-05	0.000483	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RAC1—dilated cardiomyopathy	7.28e-05	0.000461	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AGT—dilated cardiomyopathy	6.96e-05	0.000441	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.71e-05	0.000425	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.14e-05	0.000389	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RAC1—dilated cardiomyopathy	6.06e-05	0.000384	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AGT—dilated cardiomyopathy	5.79e-05	0.000367	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GPX1—dilated cardiomyopathy	5.67e-05	0.000359	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.6e-05	0.000355	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CD36—dilated cardiomyopathy	5.52e-05	0.00035	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RAF1—dilated cardiomyopathy	5.29e-05	0.000335	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AGT—dilated cardiomyopathy	4.97e-05	0.000315	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RAF1—dilated cardiomyopathy	4.83e-05	0.000306	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	4.8e-05	0.000304	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	4.67e-05	0.000296	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	4.21e-05	0.000267	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RAF1—dilated cardiomyopathy	4.02e-05	0.000255	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—dilated cardiomyopathy	3.63e-05	0.00023	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—dilated cardiomyopathy	3.31e-05	0.00021	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.76e-05	0.000175	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.58e-05	0.000163	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.51e-05	0.000159	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.26e-05	0.000143	CbGpPWpGaD
